TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29707231

Group type: EXPERIMENTAL
Intervention: Specific training programme (four specific exercises, three difficulty levels intensified every second week, completed four times a week for 10 minutes per session over 14 weeks)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Specific training programme
Number of subjects: 72
Study: 29707528

Group type: EXPERIMENTAL
Intervention: Corrective surgery
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Palliative surgery
Number of subjects: 21
Study: 29707537

Group type: EXPERIMENTAL
Intervention: Inertial Measurement Unit sensors during daily life
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Daily-life recorded kinematics
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Daily-life activities
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Clinical assessments
Number of subjects: 4
Study: 29707565

Group type: COMPARATOR
Intervention: Normal weight women (BMI < 25)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Overweight women (BMI 25-29.9)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Obese women (BMI ≥ 30)
Number of subjects: 207
Study: 29708007

Group type: EXPERIMENTAL
Intervention: Intervention to improve physical function and caregiver perceptions
Number of subjects: 0
Study: 29708906

Group type: EXPERIMENTAL
Intervention: TempZHF (SpotOn sensor)
Number of subjects: 49

Group type: COMPARATOR
Intervention: TempEso (oesophageal probe)
Number of subjects: 49

Group type: COMPARATOR
Intervention: TempArt (thermodilution arterial catheter)
Number of subjects: 49
Study: 29709062

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy followed by radio-immunotherapy and 2 years of rituximab maintenance
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Radio-immunotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Post radio-immunotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Post treatment
Number of subjects: 33
Study: 29709335

Group type: EXPERIMENTAL
Intervention: Self-management behavior
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Adherence to insulin therapy
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Foot care
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Healthy eating
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Interest in improving healthy eating and physical activity
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Interest in improving self-management behaviors
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Healthcare provider communication about A1c
Number of subjects: 1055
Study: 29710075

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29710208

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 42
Study: 29710226

Group type: EXPERIMENTAL
Intervention: Sufficient functional health literacy (FHL)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Problematic functional health literacy (FHL)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Inadequate functional health literacy (FHL)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Inadequate FHL
Number of subjects: 704

Group type: COMPARATOR
Intervention: Functional health literacy groups
Number of subjects: 704
Study: 29710408

Group type: EXPERIMENTAL
Intervention: PreventADALL intervention
Number of subjects: 0
Study: 29712625

Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based substance use brief intervention (SUBI)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard HIV counseling, testing, and referral (CTR)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: CTR followed by SUBI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: SUBI followed by CTR
Number of subjects: 600
Study: 29712627

Group type: EXPERIMENTAL
Intervention: Remote collaborative care program (n=111)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (n=139)
Number of subjects: 250
Study: 29712654

Group type: EXPERIMENTAL
Intervention: Single-Dose Oral LCB01-0371, a novel oxazolidinone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29713194

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 29713483

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 693

Group type: COMPARATOR
Intervention: ESC-SCORE
Number of subjects: 693
Study: 29713493

Group type: EXPERIMENTAL
Intervention: EcN suspension orally for 3 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (observation only)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: EcN treatment
Number of subjects: 62
Study: 29713498

Group type: EXPERIMENTAL
Intervention: ramucirumab+FOLFIRI
Number of subjects: 1057

Group type: COMPARATOR
Intervention: placebo+FOLFIRI
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: bevacizumab+FOLFIRI
Number of subjects: 1057

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 1057
Study: 29713524

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of Ranibizumab (IVR)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intravitreal injection of Bevacizumab (IVB)
Number of subjects: 33
Study: 29713840

Group type: EXPERIMENTAL
Intervention: Goal Achievement Training (GAT)
Number of subjects: 0
Study: 29713930

Group type: EXPERIMENTAL
Intervention: Robotic-assisted transabdominal preperitoneal (R-TAPP) hernia repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29713962

Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin Glargine U100
Number of subjects: 0
Study: 29714167

Group type: EXPERIMENTAL
Intervention: Raltegravir (RTG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (TDF/FTC)
Number of subjects: 20
Study: 29714603

Group type: EXPERIMENTAL
Intervention: GDF-15 centile values (age-dependent)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: GDF-15 centile values (≥95th vs <95th)
Number of subjects: 268
Study: 29715056

Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg per day after an initial dose ramp up
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Venetoclax for patients who received prior kinase inhibitors
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 158
Study: 29715516

Group type: EXPERIMENTAL
Intervention: VVS prediction algorithm with noninvasive HR and SBP analysis
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: VVS prediction algorithm using only HR and HR variability (without SBP)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: VVS prediction algorithm
Number of subjects: 140
Study: 29716439

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29716559

Group type: EXPERIMENTAL
Intervention: 13-week diabetes prevention program including 5 half-day group sessions and web/telephone-based support
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 59
Study: 29716580

Group type: EXPERIMENTAL
Intervention: TCApp combined with standard face-to-face CBT
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard face-to-face CBT alone
Number of subjects: 250
Study: 29716605

Group type: EXPERIMENTAL
Intervention: GSA-Online plus
Number of subjects: 0
Study: 29716640

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg loading dose followed by 5 mg/kg/h maintenance infusion)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 147
Study: 29717148

Group type: EXPERIMENTAL
Intervention: HIV sequence data analysis
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Clustering individuals
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Clusters consisting exclusively of men
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Clusters containing sequences from more than one region
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Clusters linking sequences with Los Alamos database
Number of subjects: 2774
Study: 29717351

Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Model predicting HP polyp size
Number of subjects: 255
Study: 29717760

Group type: EXPERIMENTAL
Intervention: Hematopoietic and vascular diseases
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Musculo-skeletal diseases
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Respiratory diseases
Number of subjects: 1181
Study: 29718280

Group type: EXPERIMENTAL
Intervention: Auditory Brainstem Implant (ABI)
Number of subjects: 10
Study: 29718281

Group type: EXPERIMENTAL
Intervention: Alström syndrome (AS) patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: BMI-matched controls
Number of subjects: 38
Study: 29718334

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 20
Study: 29718390

Group type: COMPARATOR
Intervention: 10 mg/kg rifampicin (reference arm)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 20 mg/kg rifampicin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 25 mg/kg rifampicin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 30 mg/kg rifampicin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 35 mg/kg rifampicin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 40 mg/kg rifampicin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 50 mg/kg rifampicin (predicted)
Number of subjects: 83
Study: 29719139

Group type: EXPERIMENTAL
Intervention: Sinus surgery
Number of subjects: 128
Study: 29719414

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study: 29719492

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2700
Study: 29719517

Group type: EXPERIMENTAL
Intervention: Play2Sleep intervention during a home visit
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard public health nursing information
Number of subjects: 60
Study: 29719876

Group type: EXPERIMENTAL
Intervention: Usual care plus individualised caregiver education
Number of subjects: 324

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 324
Study: 29720163

Group type: EXPERIMENTAL
Intervention: mRDT tested children in moderate-to-high transmission setting
Number of subjects: 18497

Group type: EXPERIMENTAL
Intervention: Pre-referral rectal artesunate treatment
Number of subjects: 18497

Group type: EXPERIMENTAL
Intervention: ACT prescribed in low-transmission setting
Number of subjects: 18497

Group type: COMPARATOR
Intervention: CHW referral advice
Number of subjects: 18497
Study: 29720190

Group type: EXPERIMENTAL
Intervention: Functional dyspepsia patients
Number of subjects: 124
Study: 29720196

Group type: EXPERIMENTAL
Intervention: Physical fitness (measured with 11 fitness tests covering flexibility, strength, balance, and endurance)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Functional reach (part of physical fitness assessment)
Number of subjects: 62
Study: 29720224

Group type: EXPERIMENTAL
Intervention: Docetaxel and cyclophosphamide (TC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-TC chemotherapy regimens
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 29720225

Group type: EXPERIMENTAL
Intervention: Supervised endurance exercise training combined with tocilizumab (ET)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: No exercise combined with tocilizumab (NT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Supervised endurance exercise training combined with saline (EP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No exercise combined with placebo (NP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Resistance exercise and placebo (RP)
Number of subjects: 75
Study: 29720248

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Definition of further bleeding (varied criteria, assessment, and time-point)
Number of subjects: 0
Study: 29720277

Group type: EXPERIMENTAL
Intervention: Optimal PEEP titration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tidal volume adjustment
Number of subjects: 0
Study: 29720397

Group type: EXPERIMENTAL
Intervention: SERMs
Number of subjects: 22969

Group type: COMPARATOR
Intervention: AIs
Number of subjects: 22969
Study: 29720439

Group type: EXPERIMENTAL
Intervention: Telemedicine-based vascular neurologist (TM-VN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Onboard vascular neurologist (OB-VN)
Number of subjects: 50
Study: 29720487

Group type: EXPERIMENTAL
Intervention: High heterogeneity of intratumoral metabolic activity as assessed by baseline 18FDG-PET/CT scan
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-line therapy for PMBCL
Number of subjects: 0
Study: 29720734

Group type: EXPERIMENTAL
Intervention: G-CSF, cladribine, high-dose cytarabine, and dose-escalated mitoxantrone (GCLAM)
Number of subjects: 121

Group type: COMPARATOR
Intervention: 7 + 3 regimen (not explicitly detailed in the abstract)
Number of subjects: 121
Study: 29721017

Group type: EXPERIMENTAL
Intervention: Elevated levels of miR-24, miR-30d, and miR-146a in subjects with obesity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SFRP4 levels in AbdAT
Number of subjects: 0
Study: 29721364

Group type: EXPERIMENTAL
Intervention: Audio Recording for Independent Confirmation of Clinical Assessments
Number of subjects: 0
Study: 29721378

Group type: EXPERIMENTAL
Intervention: Vemurafenib (BRAF inhibitor) and aldesleukin (interleukin-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29721545

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS) with cervical-transoral robotic oropharyngectomy and free flap reconstruction
Number of subjects: 3
Study: 29722789

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weighted prevalence of regorafenib toxicity profile and dose reduction
Number of subjects: 0
Study: 29722823

Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPV23
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PPV23
Number of subjects: 40
Study: 29722835

Group type: EXPERIMENTAL
Intervention: Catheter salvage strategy (successful antimicrobial therapy with retained CVC at discharge)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Monoinfections
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Polyinfections
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Causative microorganism: Coagulase-negative Staphylococci (CoNS)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Causative microorganism: Staphylococcus aureus
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Causative microorganism: Enterobacteriaceae
Number of subjects: 715

Group type: COMPARATOR
Intervention: Retained CVC
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Enterobacteriaceae
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Overall CRBSI
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: CRBSI relapse
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: CRBSI recurrence
Number of subjects: 715
Study: 29722836

Group type: EXPERIMENTAL
Intervention: Iodine intake ≥250-299 μg/d in 7- to 10-y-old children
Number of subjects: 2224

Group type: EXPERIMENTAL
Intervention: Iodine intake ≥300-399 μg/d in 11- to 14-y-old children
Number of subjects: 2224

Group type: EXPERIMENTAL
Intervention: Habitual iodine intake
Number of subjects: 2224

Group type: EXPERIMENTAL
Intervention: Thyroid volume and goiter
Number of subjects: 2224

Group type: EXPERIMENTAL
Intervention: Recommended iodine intake levels
Number of subjects: 2224
Study: 29722838

Group type: EXPERIMENTAL
Intervention: Maternal intake of total vitamin A (≥2031 RAEs/d)
Number of subjects: 61676

Group type: EXPERIMENTAL
Intervention: Maternal intake of total vitamin D (≥13.6 µg/d)
Number of subjects: 61676

Group type: EXPERIMENTAL
Intervention: Maternal intake of both vitamins A and D in the highest quintiles
Number of subjects: 61676

Group type: EXPERIMENTAL
Intervention: Infant supplementation with vitamin D or cod liver oil
Number of subjects: 61676

Group type: EXPERIMENTAL
Intervention: Excess vitamin A (≥2.5 times the recommended intake) during pregnancy
Number of subjects: 61676

Group type: EXPERIMENTAL
Intervention: Vitamin D intake close to recommendations
Number of subjects: 61676
Study: 29722851

Group type: EXPERIMENTAL
Intervention: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 2
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 3
Number of subjects: 2060

Group type: EXPERIMENTAL
Intervention: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 3 (stratified by race)
Number of subjects: 2060

Group type: COMPARATOR
Intervention: Whole-fat milk consumption
Number of subjects: 2060
Study: 29723161

Group type: EXPERIMENTAL
Intervention: Metreleptin treatment for 14 days (initiation cohort)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metreleptin treatment for 6 months on an ad libitum diet (initiation cohort)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Withdrawal from metreleptin for 14 days (withdrawal cohort)
Number of subjects: 22
Study: 29723397

Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg daily
Number of subjects: 75
Study: 29723634

Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR) followed by non-surgical treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-surgical treatment alone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Written advice
Number of subjects: 200
Study: 29723689

Group type: EXPERIMENTAL
Intervention: MH test (in vitro method using monocyte-derived hepatocyte-like cells)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Drugs not toxic to MH cells
Number of subjects: 40
Study: 29724167

Group type: EXPERIMENTAL
Intervention: Vemurafenib (960 mg twice daily)
Number of subjects: 0
Study: 29724294

Group type: EXPERIMENTAL
Intervention: ABCC2 rs2273697 AA genotype
Number of subjects: 187
Study: 29724397

Group type: EXPERIMENTAL
Intervention: GFF MDI 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) twice daily for 7 days with VHC
Number of subjects: 80

Group type: COMPARATOR
Intervention: GFF MDI 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) twice daily for 7 days without VHC
Number of subjects: 80
Study: 29724706

Group type: EXPERIMENTAL
Intervention: Hands-free + challenge walking
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hands-free walking (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 29724735

Group type: EXPERIMENTAL
Intervention: Chronic stress model during pregnancy
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Multidisciplinary approach including psychological resources and biophysiological and genetic profiles
Number of subjects: 260
Study: 29724899

Group type: EXPERIMENTAL
Intervention: Pinometostat (EPZ-5676)
Number of subjects: 0
Study: 29724902

Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 0
Study: 29724973

Group type: EXPERIMENTAL
Intervention: Observational registry of heart failure with mid-range and preserved ejection fraction (APOLLON trial)
Number of subjects: 1065
Study: 29725840

Group type: EXPERIMENTAL
Intervention: Pallidal deep brain stimulation (Gp-DBS)
Number of subjects: 2
Study: 29726024

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention including educational steps (written information in child's native language and follow-up telephone calls) and monitoring steps (Eidus-Hamilton test and follow-up questionnaire)
Number of subjects: 359
Study: 29726782

Group type: EXPERIMENTAL
Intervention: Laser interstitial thermal (LITT) ablation
Number of subjects: 42
Study: 29726923

Group type: EXPERIMENTAL
Intervention: Brontictuzumab administered intravenously at 1.5 mg/kg every 3 weeks (Q3W) during expansion phase.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Brontictuzumab administered intravenously at various dose levels during dose escalation.
Number of subjects: 48
Study: 29726948

Group type: EXPERIMENTAL
Intervention: Sustained recovery from MAM
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: Relapsed to MAM once
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: Relapsed to MAM multiple times
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: Developed severe acute malnutrition (SAM)
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: Declining HAZ
Number of subjects: 1487
Study: 29727073

Group type: EXPERIMENTAL
Intervention: Ketamine infusions (0.5 mg/kg)
Number of subjects: 15
Study: 29727383

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ribavirin (RBV) for 24 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Simeprevir for 12 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir for 24 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir + Ribavirin (RBV) for 12 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 62

Group type: COMPARATOR
Intervention: HCC recurrence
Number of subjects: 62
Study: 29728114

Group type: EXPERIMENTAL
Intervention: BALANCE Dietary Index (DI)
Number of subjects: 2044
Study: 29728137

Group type: EXPERIMENTAL
Intervention: High MIF levels
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MIF levels
Number of subjects: 62
Study: 29728150

Group type: EXPERIMENTAL
Intervention: PRE-DELIRIC
Number of subjects: 2178

Group type: COMPARATOR
Intervention: E-PRE-DELIRIC
Number of subjects: 2178

Group type: EXPERIMENTAL
Intervention: Two-stage calculation using E-PRE-DELIRIC and updated with PRE-DELIRIC after 24 hours
Number of subjects: 2178
Study: 29728199

Group type: EXPERIMENTAL
Intervention: Point-of-care device (i-STAT, Abbott Laboratories)
Number of subjects: 1170